SureTrader Advertisement PRTC
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: Peaser, conix, Phaeton, $Pistol Pete$
Search This Board:
Last Post: 5/25/2016 2:46:32 PM - Followers: 347 - Board type: Free - Posts Today: 14


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Current Report Filing (8-k) 05/24/2016 04:27:18 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 05/18/2016 08:02:16 AM
MNKD News: Initial Statement of Beneficial Ownership (3) 05/18/2016 08:00:42 AM
MNKD News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 05/10/2016 09:14:46 AM
MNKD News: Current Report Filing (8-k) 05/10/2016 08:40:25 AM
News News Alert: Current Report Filing (8-k) 05/24/2016 04:27:18 PM
#18442  Sticky Note Great shareholders meeting last Thursday. If you want Phaeton 05/23/16 11:03:26 PM
#17438  Sticky Note MNKD Manipulation Story: Peaser 02/01/16 09:03:36 AM
#16574  Sticky Note $MNKD ~ MannKind Corp. due diligence report $Pistol Pete$ 12/18/15 01:14:52 AM
#18464   MNKD WEEKLY CHART TREND1 05/25/16 02:46:31 PM
#18463   Higher highs higher lows people dmcc2087 05/25/16 02:22:52 PM
#18462   Bought 10,000 shares today volume is increasing dmcc2087 05/25/16 02:22:44 PM
#18461   BIGINVESTORS If you feel MNKD is going up 300% TREND1 05/25/16 02:17:01 PM
#18460   Rumours about Mannkind waiting for EMA decision biginvestors 05/25/16 01:53:35 PM
#18459   I agree a lawsuit against a BP is Hypi 05/25/16 12:23:46 PM
#18458   NO BUY OUTS TREND1 05/25/16 12:14:43 PM
#18457   Is one of the largest pharmaceutical companies interested biginvestors 05/25/16 12:07:21 PM
#18456   They might in a years time. bakersson 05/25/16 11:59:29 AM
#18455   bakersson MNKD does not the dollars to hirer lawyers. TREND1 05/25/16 11:30:26 AM
#18454   If you watch the shareholder meeting you hear bakersson 05/25/16 11:18:11 AM
#18453   Looking real good the past week dmcc2087 05/25/16 10:25:51 AM
#18452   Volume is picking up I am In dmcc2087 05/25/16 10:25:39 AM
#18451   Thanks for posting the link to the shareholder bakersson 05/25/16 10:24:43 AM
#18450   Its all about time and money. If they Hypi 05/24/16 11:17:48 PM
#18449   It's so tempting I'm completely out of the makers dmcc2087 05/24/16 09:56:31 PM
#18448   Any other thoughts dmcc2087 05/24/16 09:56:10 PM
#18447   $MNKD Weekly Ichimoku Chart http://stockcharts $Pistol Pete$ 05/24/16 08:52:22 PM
#18446   Nice close today and I called the bottom Hypi 05/24/16 04:10:00 PM
#18445   Thank you for video. TREND1 05/24/16 12:18:45 AM
#18444   alot of buys showing up. news an 1.50 harry crumb 05/24/16 12:00:45 AM
#18443   sure do harry crumb 05/23/16 11:54:37 PM
#18442   Great shareholders meeting last Thursday. If you want Phaeton 05/23/16 11:03:26 PM
#18441   U think dmcc2087 05/23/16 09:01:29 PM
#18440   Volume low looking for a buy out or bounce dmcc2087 05/23/16 09:00:26 PM
#18439   Yep this is a good buy at this Brentpdc 05/23/16 08:39:45 PM
#18438   Anyone recommend buying here dmcc2087 05/23/16 03:04:22 PM
#18437   MNKD SHORT INTEREST conix 05/23/16 10:57:10 AM
#18436   that they charge a percentage on penny stocks tyfoidhana 05/22/16 08:54:24 PM
#18435   Sorry but thats not true kugel 05/22/16 08:40:41 PM
#18434   Please update the sticky Phaeton 05/22/16 08:19:32 PM
#18433   Nothing has changed at Scottrade as far as tyfoidhana 05/22/16 07:22:31 PM
#18432   Nothing special just 10000 share of MNKD under kugel 05/22/16 07:05:21 PM
#18431   MNKD weekly TREND1 05/22/16 11:57:43 AM
#18430   When I buy online it's generally 7.95 at Phaeton 05/21/16 06:22:15 PM
#18429 biginvestors 05/21/16 04:17:47 PM
#18428   Your right there no Matt at MNKD ??? md1225 05/21/16 09:19:27 AM
#18427   Exactly, it is a bet. A risky one. Larrydavid12345 05/21/16 12:19:28 AM
#18426   "Matt"? Who is Matt? Where did you pick Larrydavid12345 05/21/16 12:10:42 AM
#18425   $MNKD Daily Chart $Pistol Pete$ 05/20/16 08:55:48 PM
#18424   Apologies as for Matt he should not have lied. md1225 05/20/16 06:54:14 PM
#18422   time to quietly load up again for a harry crumb 05/20/16 05:07:24 PM
#18421   Credibility is very important in all things/ When conix 05/20/16 04:21:41 PM
#18420   md1225 your wife must be ticked off at Hypi 05/19/16 06:05:07 PM
#18419   kugel I have MER via Bank of America TREND1 05/19/16 01:28:17 PM
#18418   Thanks kugel 05/19/16 11:18:29 AM
#18417   I have E*.....those share would cost me $9.99 bobl17211 05/19/16 09:47:17 AM
#18416   This is biotech trading. Matt lied period and md1225 05/19/16 06:32:01 AM
#18415   Thanks!! kugel 05/19/16 06:26:25 AM
#18414   I switched to Fidelity a number of years Denise Chanterelle 05/18/16 11:51:15 PM